NPI registry status
Active
2026 NPPES data Rheumatology Physician NPI 1164542197 MD
Verify on CMS → Meggan Mackay, MD
Rheumatology Physician in Manhasset, New York.
This profile is drawn from the federal National Provider Identifier Registry (CMS NPPES), which lists more than 7 million U.S. healthcare providers - including 6,377 in Rheumatology Physician, and covers specialty classification, practice address, and Medicare Part D prescribing data when reported. According to CMS, every field reflects the provider's official federal registration, see our methodology.
Federal data, no proprietary rating.
We show these CMS records as-is - no composite score, no star rating, no editorial opinion layered on top.
Prescribing volume
746
Medicare Part D claims · 48 beneficiaries · Rheumatology Physician avg: 2K
Generic prescribing
90%
generic claims · 10% brand-name · higher generic rates reduce patient out-of-pocket costs
MIPS score
91.3/100
▲ 8 pts above national avg 83.5 · Exceptional
Source: CMS Medicare Part D Prescriber Public Use File, 2024
What the federal data shows
Meggan Mackay, MD reported a CMS MIPS final score of 91.3/100 - above the 83.5 national average - and filed 746 Medicare Part D claims in 2024.
- 91.3/100
- MIPS score · +8 vs avg
- 746
- Part D claims, 2024
- 90%
- generic prescribing
- Likely
- board-certified (heuristic)
Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) - no proprietary rating or editorial opinion is applied.
Federal trust snapshot
What official records show about Meggan Mackay, MD
Federal records show an active NPI with both Medicare prescribing volume and a measured CMS quality score — objective registry data, not patient reviews.
- Verified
NPI registry status
Active listing in the CMS National Provider Identifier Registry (NPI 1164542197), first enumerated 03/31/2007.
Source: CMS NPPES
- Reported
Medicare Part D participation
Filed 746 Medicare Part D prescription claims in the 2023 CMS public use file — indicates active Medicare prescribing participation.
Source: CMS Part D Prescriber PUF
- Reported
CMS quality reporting (MIPS)
Reported a CMS MIPS final score of 91.3/100 in the Quality Payment Program — a federal quality measure, not a patient review.
Source: CMS Quality Payment Program
- Reported
Board certification signal
Heuristic suggests board-certified status based on ABMS-eligible specialty taxonomy plus active CMS participation signals — not a direct ABMS verification.
- Reported
Hospital affiliations
1 CMS Care Compare hospital affiliation on record — practice footprint from the Doctors and Clinicians file.
Source: CMS Care Compare
- State context
State board disciplinary context
New York statewide board action statistics are published annually — these figures describe aggregate state activity, not Meggan Mackay, MD's individual license status. Verify directly with the state medical board.
Source: NYSBPMC annual report 2023
- Not in federal data
Individual sanction lookup
PlainDoctor does not publish per-provider disciplinary determinations. Confirm current license and any individual actions through the state medical board or FSMB verification service.
Source: State medical board / FSMB
This trust snapshot summarizes only what appears in federal CMS/NPPES public records. It is not a composite score, star rating, patient review, or clinical recommendation. PlainDoctor never fabricates reviews or AggregateRating schema.
CMS NPPES provider registry desk
NPI 1164542197 · Rheumatology Physician
NPI-10 · ENUM-MID · TAX-MID · MIPS-ABOVE · RX-LIGHT · BOOK-THIN · PHOTO-FINISH
- NPI-10 1164542197
- ENUM-MID 2007
- TAX-MID 6K Rheumatology Physician
- MIPS-ABOVE 91.3/100
- RX-LIGHT 746
- BOOK-THIN 467 in New York
- PHOTO-FINISH Ivana Ilic · ±0.0
MIPS final-score neighbourhood
Same-specialty nationwide peers by CMS final score, not geographic proximity
- Mackay · this pr…
Mackay · this provider
91.3 MIPS pts
- Kyle Park · high…
Kyle Park
91.3 MIPS pts
- Ivana Ilic · near
Ivana Ilic
91.3 MIPS pts
- Hamead Moshrefi …
Hamead Moshrefi
91.3 MIPS pts
- Jonathan Paramo …
Jonathan Paramo
91.3 MIPS pts
What this shows Nearest measured MIPS peers for this NUCC specialty (2023 performance year).
Meggan Mackay, MD's MIPS score vs every measured U.S. clinician
CMS Merit-based Incentive Payment System (MIPS) final score, 2023, the federal quality measure. Clinicians whose score CMS assigned without scoring any category are excluded.
91 ≥ 61st percentile 61% of 454,083 measured providers are in lower value bands
Each bar is a band; taller bars hold more measured providers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
The percentile is a conservative whole-score-point band: it counts only measured clinicians in lower score bands. A CMS MIPS metric is not a recommendation or a clinical-quality rating by PlainDoctor. See methodology § corpus placement.
Source CMS Merit-based Incentive Payment System (MIPS) · 2023
Where Meggan Mackay, MD sits
This provider among rheumatology physician peers
Across the 1,970 rheumatology physician providers who report both Medicare Part D prescribing and a MIPS quality score, Meggan Mackay, MD writes more Part D claims than 20% of them and scores higher on MIPS quality than 60% - placing this provider in the lower-volume, high-quality quadrant. Volume reflects patient-panel size and specialty, not quality; the two axes are independent.
Each dot is one rheumatology physician peer from a representative sample of 60; the gold marker is Meggan Mackay, MD. Source: CMS Medicare Part D Prescriber data and the CMS Merit-based Incentive Payment System, 2023.
✓
Board certification likely (heuristic, not verified)
Meggan Mackay, MD practices in an ABMS-board-eligible specialty and shows active CMS Medicare participation + MIPS quality reporting + 1 hospital affiliation - signals consistent with board-certified status. For verified board certification, see CertificationMatters.org (the official ABMS public lookup).
What does the federal data show about Meggan Mackay, MD?
High performer (top quartile)Primary specialty
Rheumatology Physician
Medicare Part D claims
746 64% vs specialty avg
MIPS final score
91.3/100 7.8 pts vs avg
Specialty distribution in New York
How Rheumatology Physician compares to other specialties among New York providers
Medicare quality performance, MIPS
Meggan Mackay, MD's 2023 MIPS final score plotted against the Rheumatology Physician national average
- MIPS Final Score
- 91.3/100
- vs 83.5 national avg · 2023 performance year
How MIPS and board certification work
The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.
Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).
Practice Address
Provider Details
| NPI | 1164542197 |
|---|---|
| Specialty | Rheumatology Physician |
| Credentials | MD |
| Gender | Female |
| NPI Issued | 03/31/2007 |
CMS Quality Score (MIPS)
Merit-based Incentive Payment System (MIPS) scores from CMS, 2023 performance year.
91.2532
Final Score
Measured-score avg: 83.5
74.9203
Quality
91.6794
Promoting Interoperability
Reporting: Alternative Payment Model
Hospital and facility affiliations
Facilities where Meggan Mackay, MD bills Medicare from. Star ratings (1-5) are CMS Hospital Compare's "Hospital overall rating" - a composite of mortality, readmission, patient experience, safety, timely care, and efficient use of medical imaging measures. Source: CMS Care Compare.
North Shore-Lij Medical PC
Manhasset, NY
Affiliations sourced from CMS Doctors and Clinicians National Downloadable File; hospital ratings from CMS Hospital General Information dataset (cross-referenced by facility name + state).
License & disciplinary context - New York NYSBPMC 2023 annual report
Aggregate state board data only, NOT a determination of any individual provider's status. The figures below describe statewide disciplinary activity across all ~100K New York medical licensees in 2023 - they are NOT specific to Meggan Mackay, MD. To verify Meggan Mackay, MD's current license status, search the NYSBPMC public license lookup directly, or check the Federation of State Medical Boards (FSMB) verification service.
312
Total board actions, New York 2023
Across 302 cases
3.12
Actions per 1,000 licensees
New York statewide rate
probation
Most common action type
89 cases
NYSBPMC publishes annual disciplinary statistics as part of public-record reporting under each state's Administrative Procedure Act. See the full breakdown by action type and year on the New York disciplinary trends page. Cross-checked against FSMB U.S. Medical Regulatory Trends.
Brand vs generic prescribing mix · Typical
Meggan Mackay, MD - brand share 10.0%
Rheumatology Physician average
10% brand-name claims vs 90% generic, on 746 2024 Medicare Part D claims.
The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.
Medicare Part D Prescribing Data
CMS Medicare Part D prescriber-level data for calendar year 2024.
746
Total Claims
$247K
Total Drug Cost
48
Medicare Beneficiaries
Prescribing Breakdown
- 30-Day Fills
- 1,066.633
- Total Day Supply
- 31,255
- Brand vs Generic
- 10% brand / 90% generic
- Brand Drug Cost
- $226K
- Generic Drug Cost
- $21K
- Opioid Claims
- 13 (1.7% rate)
- Antibiotic Claims
- 19
Patient Demographics
- Average Patient Age
- 57.6 years
- Avg HCC Risk Score
- 1.95
- Age Distribution
- <65: 29, 65-74: 11, 75-84: N/A, 85+: N/A
Top Prescribed Drugs (Medicare Part D)
Top drugs by claim count for calendar year 2024. Based on Medicare Part D data only.
What Meggan Mackay, MD prescribes most
Top Medicare Part D drugs by claim count, 2024
- Hydroxychloroquine…
Hydroxychloroquine Sulfate
171 claims
- Prednisone
Prednisone
72 claims
- Benlysta 47
Benlysta
47 claims
- Leflunomide 33
Leflunomide
33 claims
- Ibuprofen 31
Ibuprofen
31 claims
- Mycophenolate Mofe… 31
Mycophenolate Mofetil
31 claims
- Metoprolol Succinate 20
Metoprolol Succinate
20 claims
- Lisinopril 18
Lisinopril
18 claims
| Drug | Claims |
|---|---|
| Hydroxychloroquine Sulfate | 171 |
| Prednisone | 72 |
| Benlysta Belimumab | 47 |
| Leflunomide | 33 |
| Ibuprofen | 31 |
| Mycophenolate Mofetil | 31 |
| Metoprolol Succinate | 20 |
| Lisinopril | 18 |
| Mycophenolic Acid Mycophenolate Sodium | 18 |
| Hydroxyzine Hcl | 14 |
* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.
Rheumatology Physician Overview
How Meggan Mackay, MD fits within the Rheumatology Physician landscape nationally.
6,377
Rheumatology Physician Providers in US
52
States with Rheumatology Physician
2,058
Avg Claims per Provider
Meggan Mackay, MD's 746 claims are below the specialty average of 2,058.
Nationwide Rheumatology Physician peers with similar MIPS or enrollment year
Two federal-record peer sets for Mackay, both outside New York so the neighborhoods are not geographic containment.
Similar MIPS final score
Nearest same-specialty clinicians by CMS MIPS final score (91.3 here).
Same NPPES enumeration year (2007)
Same-specialty clinicians who entered the NPI registry in the same calendar year, outside this state.
Nearby Rheumatology Physician Providers in New York
Other clinicians with the same primary specialty enrolled in New York, drawn from the same CMS NPPES roster as Mackay.
One of 467 Rheumatology Physician providers enrolled in New York, 5 are shown here.
Dr. Mary Abdulky
MD
Syracuse, NY
Dr. Ilana Abeles
M.D., PHD
Rochester, NY
Dr. Jihad Abialmouna
M.D.
West Amherst, NY
Dr. Omar Abialmouna
MD
Buffalo, NY
Dr. Irina Abramova
D.O
New Hyde Park, NY
Compare Rheumatology Physician nationally: see state-by-state distribution →
Frequently Asked Questions
What is Meggan Mackay, MD's specialty? ▼
Meggan Mackay, MD specializes in Rheumatology Physician and practices in Manhasset, New York. Credentials: MD.
How much does Meggan Mackay, MD prescribe under Medicare Part D? ▼
In 2024, Meggan Mackay, MD wrote 746 Medicare Part D claims totaling $247K in drug costs for 48 beneficiaries.
What is Meggan Mackay, MD's Medicare quality score? ▼
Meggan Mackay, MD has a CMS MIPS Final Score of 91.3/100 (Quality: 74.9). The average MIPS Final Score across the 454,083 clinicians with at least one published category score is 83.5; clinicians whose score CMS assigned without scoring any category are excluded from that average. Source: CMS Merit-based Incentive Payment System (MIPS) 2023.
Where is Meggan Mackay, MD located? ▼
Meggan Mackay, MD is located at 350 COMMUNITY DR, Manhasset, NY, 11030. Phone: (516) 562-3838.
What is Meggan Mackay, MD's NPI number? ▼
Meggan Mackay, MD's National Provider Identifier (NPI) is 1164542197, issued on 03/31/2007.
Does Meggan Mackay, MD prescribe more brand-name or generic drugs? ▼
Meggan Mackay, MD's prescribing is 10% brand-name and 90% generic drugs by claim count, with $226K in brand drug costs.
Does Meggan Mackay, MD prescribe opioids? ▼
Yes, Meggan Mackay, MD had 13 opioid claims in 2024 with an opioid prescribing rate of 1.7%.
How many Rheumatology Physician providers are there in the US? ▼
There are 6,377 Rheumatology Physician providers across 52 states in the US. The average Rheumatology Physician provider writes 2,058 Medicare Part D claims per year.
What drugs does Meggan Mackay, MD prescribe most often? ▼
Based on 2024 Medicare Part D data, Meggan Mackay, MD's most frequently prescribed drugs include Hydroxychloroquine Sulfate, Prednisone, Benlysta. This reflects Medicare Part D prescriptions only and does not include commercial insurance or other payer types.
Does Meggan Mackay, MD accept Medicare? ▼
Meggan Mackay, MD appears in CMS Medicare data with 746 Part D claims and 48 Medicare beneficiaries in 2024. Contact the provider's office directly to confirm current Medicare enrollment and accepted plans.
How can I verify Meggan Mackay, MD's credentials? ▼
Meggan Mackay, MD's NPI is 1164542197 with credentials MD. You can verify this through the NPPES NPI Registry, check state medical board records, and confirm board certification through the ABMS or AOA.
Data Sources
View source datasets and methodology notes
- Provider Directory
- CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
- Specialty Classification
- NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
- Prescribing Data
- CMS Medicare Part D Prescriber Public Use File (2024). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
- Quality Performance
- CMS Merit-based Incentive Payment System (MIPS) - 2023 performance year.
- Limitations
- Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.
See our complete data methodology for details on how we collect and process government data.
Data as of August 2026 (NPPES) / 2024 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).
Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology
Every figure on PlainDoctor is rendered directly from the federal CMS NPPES registry, Medicare Part D, MIPS, and Open Payments records, no number is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of August 2026.